PreciseDX Aims To ‘Enrich’ Standard Of Care For Breast Cancer Recurrence Prediction

The New York-based augmented intelligence health care services provider has secured $20.7m in series B funding to support clinical validation and commercialization of its AI-powered breast cancer morphology diagnostic test PreciseBreast. The company intends for its test to advance current approaches to recurrence prediction comprising clinician histopathology assessment and genomic testing.

PreciseDx will leverage $20.7m in new funding to accelerate validation testing for PreciseBreast, an artificial intelligence (AI)- powered test that analyzes breast cancer cell morphology to predict 6-year risk of recurrence in early-stage breast cancer patients.

Massachusetts-based investment adviser Eventide Asset Management led the series B funding round, PreciseDx announced on 21 August. Other participants included...